DLA Piper appears to have settled a case brought by a Queen’s Counsel alleging it skipped out on $274,000 in fees because the firm’s client had not paid its bill.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
A judge’s decision to halt questioning about ASIC emails in a class action trial over the 2008 collapse of finance group Octaviar didn’t shut the case down, the Public Trustee of Queensland has told the Full Federal Court, calling the appeal of the class action’s dismissal “completely misconceived”.
Critical emails from ASIC regarding a $250 million loan facility to Octaviar Group before its 2008 collapse were not only overlooked by the Public Trustee of Queensland in its role overseeing the firm’s finances but were wrongly deemed irrelevant by the judge that heard the case, the Full Federal Court was told.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
Fairfax Media is moving forward with a lawsuit against Network Ten over the alleged infringement of its “Boss” trade mark, even after the TV broadcaster agreed to stop using the name.
Law firms Maurice Blackburn and Phi Finney McDonald have stepped back from a proposed consolidation of their class actions against the Commonwealth Bank of Australia and want to run their own cases again, but now with “harmonised” pleadings.
A judge that dismissed an investor class action against the Public Trustee of Queensland over the failure of investment firm Octaviar Group improperly intervened in the cross-examination of one of the class’ witnesses, one of the judges that will hear an appeal of the dismissal was told.
The Full Federal Court has expedited an appeal filed Christmas Eve by Sanofi-Aventis of a ruling that denied its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
The investor behind a failed class action against the Public Trustee of Queensland over the collapse of Octaviar Group has escaped a bid by the Trustee for maximum costs, with a judge ruling the case was not a “nakedly speculative venture” by the funder.